EUVIMEDEUVIMED entdecken
Crossref

Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Thomas Boat, Md Monir Hossain, Aisaku Nakamura, Michelle Hjelm, William Hardie, Matthew Wackler, Alyssa Amato, Carolyn Dress

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.27463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Thomas Boat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Me…. Hauptthemen laut MEDLINE: Body Composition, Cystic Fibrosis, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: This work was supported by an independent investigator grant from Vertex Pharmaceuticals. Vertex had no role in collection, analysis or interpretation of data….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We prospectively monitored rates of change for growth, body mass and composition, muscle strength, and FEV1 in 6−11‐year‐olds initiating ETI therapy, comparing them to those of US reference children. We assessed factors potentially contributing to rate of change and report ranges of individual variation.

Methods

Body composition was assessed using bioelectrical impedance analysis (BIA), and rates of change were analyzed using linear mixed effects regression models.

Results

At enrollment, median BMI‐Z was 0.6 (IQR: −0.2, 1.1), percent body fat (PBF) was 22.7 (14.0, 31.5), and percent predicted(pp) FEV1 was 100 (90, 106). During ETI treatment, mean Z scores for annualized change rates of BMI (0.02 ± 0.07; p = 0.74), FMI (0.02 ± 0.08; p = 0.76), and FFMI (−0.03 ± 0.07; p = 0.68) were not different from zero. The most rapid weight gain occurred in girls ( p = 0.01), 10−11‐year‐olds ( p < 0.001), and those previously treated with a modulator ( p = 0.005). Individual rates of change varied widely; PBF increased for 15 children (range: 0.7 to 10.0) and decreased for 12 (range: −0.7 to −9.5). Changes in body mass and composition were not significantly associated with changes in ppFEV1; regression coefficients were positive for FFMI (0.83) and SMMI (1.07) and negative for FMI (−0.29).

Conclusion

Healthy, well‐nourished children with CF, as a group, experienced growth and body composition changes similar to those of US children, added muscle mass, and often added more FM than FFM during ETI therapy. Individual variation underscores the need for body composition monitoring and interventions that promote healthy physical maturation for all during ETI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionCystic FibrosisAminophenolsBenzodioxolesMuscle StrengthQuinolonesIndolesPyrazolesPyrrolidinesPyridinesHumansChildFemaleMaleProspective StudiesBody Mass IndexElectric ImpedanceForced Expiratory VolumeDrug Combinations

Stichwörter der Autor:innen

ETI therapybody compositionchildrencystic fibrosisstrengthweight gain

Substanzen

AminophenolsBenzodioxolesQuinolonesivacaftorelexacaftorIndolestezacaftorPyrazolesPyrrolidinesPyridines

Autor:innen und Institutionen

  • Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Depatment of Pediatrics, Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Depatment of Pediatrics, Division of biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Department of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Förderung

  • This work was supported by an independent investigator grant from Vertex Pharmaceuticals. Vertex had no role in collection, analysis or interpretation of data…

Zitieren

APA

Boat, T., Hossain, M. M., Nakamura, A., Hjelm, M., Hardie, W., Wackler, M., Amato, A., & Dress, C. (2025). Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI). Pediatric Pulmonology. https://doi.org/10.1002/ppul.27463

Vancouver

Boat T, Hossain MM, Nakamura A, Hjelm M, Hardie W, Wackler M, et al. Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI). Pediatric Pulmonology. 2025. doi:10.1002/ppul.27463

BibTeX
@article{Boat2025,
  author = {Boat, Thomas and Hossain, Md Monir and Nakamura, Aisaku and Hjelm, Michelle and Hardie, William and Wackler, Matthew and Amato, Alyssa and Dress, Carolyn},
  title = {Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.27463}
}
Kostenlos starten →